Objective: This study aims to investigate the viability and
safety of utilizing ropinirole in combination with
nerve growth factor for the management of neurological
health in
football players.
Methods: A total of 92
athletic inpatients diagnosed with
Parkinson's disease were enrolled in this study from December 2018 to December 2020. They were randomly divided into two groups the
control group and the
research group, each comprising 46
athletic patients . The
control group received
nerve growth factor treatment , while the
research group received a combination of ropinirole and
nerve growth factor . Various
serum markers ,
brain nerve factors,
quality of life indicators ,
therapeutic outcomes, and
safety profiles were evaluated and compared between the two groups.
Results: Following
treatment , both groups exhibited a significant increase in
superoxide dismutase (SOD) levels compared to baseline, accompanied by substantial reductions in the levels of
interleukin-1 β (
IL-1 β),
tumor necrosis factor-alpha (TNF-α), and nuclear factor-kappa B P65 (NF-κB P65). Moreover, the
research group demonstrated significantly higher SOD levels and lower
IL-1 β, TNF-α, and NF-κB P65 levels compared to the
control group (P<0.05). The levels of
ciliary neurotrophic factor (
CNTF ),
brain-derived neurotrophic factor (
BDNF ),
dopamine (DA), and
serotonin (
5-HT ) significantly increased in both groups post-
treatment , with the
research group exhibiting notably higher levels of these factors compared to the
control group (P<0.05). Assessment of
cognitive function (Montreal Cognitive Assessment - MoCA), balance (Berg Balance Scale - BBS), and
activities of daily living (
ADL ) scores revealed significant improvements in both groups
after treatment . However, the
research group displayed higher MoCA and BBS scores and lower
ADL scores than the
control group (P<0.05). (AU)